DƯỢC LÍ Goodman & Gilman's The Pharmacological Basis of Therapeutics 12th, 2010

2050
INDEX
Myocardial oxygen supply,
pharmacological
modification, 752, 752f,
755–756
Myoclonic seizures, 605
Myopathy, statins and, 896, 903
Myxedema coma, 1144–1145
N
N, N-Dimiethylarginine, 102t
Nabumetone, 986
absorption, 986
adverse effects and side effects of,
986
chemistry, 986
compared to aspirin, 970t
COX isoform selectivity, 962f
distribution of, 986
dosage and administration of, 970t
elimination, 986
pharmacokinetics of, 970t, 986,
1867t
pharmacology of, 962f
plasma pharmacokinetics of, 962f
structure of, 986
therapeutic uses of, 970t, 986
N-acetyl-p-benzoquinoeimine
(NAPQI), in acetaminophen
toxicity, 75–76
N-acetyltransferases (NAT), 125, 125t,
136–138, 138t
Nadolol, 311f, 320
as antihypertensive agent, 774t
NADPH-quinone oxidoreductase
(NQO), 125t
Nafarelin, 1119t, 1122
for endometriosis, 1840
structure of, 1764t
Nafcillin, 1489
chemistry of, 1479t
properties of, 1479t
Naftidrofuryl, 772
Naftifine, 1588
for cutaneous fungal infection, 1818
NAFTIN (naftifine), 1818
Nail infections, fungal, 1818
NAION. See Nonarteritic ischemic
optic neuropathy (NAION)
NALADOR (sulprostone), 1837
Nalbuphine
actions and selectivities of, 485t
pharmacology of, 511
side effects of, 511
therapeutic uses of, 511
tolerance and dependence on, 511
NALFON 200 (fenoprofen), 989
Nalidixic acid, hypoglycemia and,
1248t
Nalorphine, actions and selectivities
of, 485t
Naloxonazine, actions and selectivities
of, 485t
Naloxone
actions and selectivities of, 485t
effects on bowel function, 1330t
for pruritus, 1828t
Naloxone benzoylhydrazone, actions
and selectivities, 485t
Naloxone hydrochloride, as antidote,
86t
Naltrexone
actions and selectivities of, 485t
for alcoholism, 642–643
pharmacokinetics of, 1867t
for pruritus, 1828t
Naltrindole, actions and selectivities
of, 485t
Name, generic, 1882
NAMs. See Negative allosteric
modulators (NAMs)
Nanophyetus salmincola, 1449
Nanotechnology, in drug delivery, 23
Naphazoline hydrochloride, for
ophthalmic use, 1789
NAPQI. See N-acetyl-pbenzoquinoeimine
(NAPQI)
NAPROSYN (naproxen), 988–989
Naproxen, 987, 988–989
absorption, 988
adverse effects and side effects of,
989
compared to aspirin, 969t
COX isoform selectivity, 962f
distribution of, 988
dosage and administration of, 969t
elimination, 988
hypoglycemia and, 1248t
pharmacokinetics of, 969t, 988–989,
1868t
pharmacology of, 962f
plasma pharmacokinetics of, 962f
structure of, 988f
therapeutic uses of, 969t
NAQUA (trichlormethiazide), 688t
Narcolepsy, sympathomimetic amines
for, 303
Nasal decongestion, alpha-adrenergic
agonists for, 302
Nasal mucosa, drug metabolism in,
126
Nasopharyngeal glands, in autonomic
nervous system, 179t
NAT. See N-acetyltransferases (NAT)
Nateglinide, 110, 1258
National Cholesterol Education
Program (NCEP)
guidelines for assessment of risk,
885–887
guidelines for treatment of
dyslipidemias, 887–889,
890, 892
National Institute of Drug Abuse
(NIDA), 80
NATO. See Nolvadex Adjuvant Trial
Organization (NATO)
Natriuretic peptide receptors, 63–64
Natriuretic peptides, 695–696
adverse effects and side effects of,
696
elimination, 696
therapeutic uses of, 696
NATURETIN (bendroflumethiazide), 688t
Nausea and vomiting, 1341
warfarin-induced, 864
Naxifylline (BG9179), 793
NCEP. See National Cholesterol
Education Program (NCEP)
NDA. See New Drug Application
(NDA)
Nebivolol, 312f, 330
as antihypertensive agent, 774t,
780–781
Nebulizers, 1035
Necator americanus, 1445
Necrotizing fasciitis, 1817
Nedocromil sodium, for ophthalmic
use, 1789
Nefazodone
disposition of, 409t
dose and dosage forms of, 403t
potencies
at human transporters for
monamine neurotransmitters,
406t
at neurotransmitter receptors, 410t
side effects of, 403t
and statins, interactions, 896
Negative allosteric modulators
(NAMs), 220
Neisseria gonorrhoeae, drug
resistance, 1841
Nelarabine, 1704
Nelfinavir, 1626t, 1655
structure of, 1648f
Nelivaptan, 717
Nematode infections, 1444–1447
Nemonapride, polymorphisms and
response to, 160t